ABTAbbott Laboratories
Is it safe?
Strong, no red flags: a safe balance sheet, clean books, and steady price behavior.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).
Mixed fundamental signals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.
Insiders were net sellers (-$46.9M, 90 days to Oct 8, 2026), selling is often routine.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Relatively steady, low volatility. Worst drawdown -40% · now 26% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can ABT take a bad year?
Abbott Laboratories carries $26.8B of net debt at 2.91× EBITDA: a load its earnings can carry.
Net debt · as at Q1 2026 · between two and four years of EBITDA, normal for a stable business
- Net debt / EBITDA
- 2.91×
Net debt / EBITDA · 0.76× a year ago · the load is going up
- Altman Z-score
- 4.48
Altman Z-score · safe zone, above 3
- Interest cover
- 14.4×
Interest cover · operating profit covers the interest bill several times over
Details›
- Total debtQ1 2026
- $34.0B
- Cash and short-term investments
- $7.29B
- Net debt
- $26.8B
- EBITDA, trailing twelve months
- $9.18B
- Operating profit, trailing twelve months
- $7.71B
- Debt / equity
- 0.65×
- Total debt / EBITDA
- 3.71×
- Annualised volatilitytwo years of daily moves
- 24%
- Worst drawdown on file
- −40%
- Below its 52-week high
- 26%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Medical Devices
The closest names by size in the same industry